Contribute Try STAT+ Today

Dr. David Fajgenbaum has nearly died not once, but five times. The cause each time was a rare disorder called Castleman disease, an affliction on the boundary between cancer and an autoimmune disorder. It caused his entire body to swell up. Previously a muscled college football player, he first became bloated, then very thin.

Fajgenbaum, who was in medical school when he got sick, did something extraordinary. He founded a patient advocacy group, the Castleman Disease Collaborative Network. But more than that, he delved into the science of his disease, and proposed the treatment that, after five relapses, has kept him healthy since. It was an existing drug, sirolimus, that no one had thought to use for Castleman disease. Football, he said, helped him deal with the failure inherent in medical research.

Now 34, Fajgenbaum details his experience in a new book, “Chasing My Cure,” in which he also writes about his mother’s death from brain cancer and the way the disease affected every aspect of his life, including his relationship with his wife. He’s an assistant professor of medicine in the Division of Translational Medicine and Human Genetics at the University of Pennsylvania in Philadelphia.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Having retired late last year from 33 years in pharmaceutical research, I thought that one part of NIH announced a couple of years ago that they were investigating approved drugs for other uses, but possibly only for reported off-label uses that hadn’t been adequately studied. I know that one project was adding data on how well SSRI antidepressants worked to reduce hot flashes in menopausal women with a focus on drugs that were or would soon be off patent in hopes they would also be more affordable.

  • It’s curious, rapamycin seems to target iron. Rapamycin is a macrolide and macrolides bind iron. “MLs can chelate iron ions in aqueous solution”

  • What a story. Thank you and congratulations on you 51/2 year remission. Makes me think that in today’s forward thinking world, particularly in science, technology and medicine, that looking back might also find more answers. Aren’t we also supposed to recycle, reuse and repurpose? What better place to consider the potential benefits than in medicine.

Comments are closed.